vs
PATHWARD FINANCIAL, INC.（CASH）与CATALYST PHARMACEUTICALS, INC.（CPRX）财务数据对比。点击上方公司名可切换其他公司
PATHWARD FINANCIAL, INC.的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.8倍（$276.3M vs $152.6M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 26.4%，领先8.1%），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 21.0%）
Pathward Financial, Inc.是一家总部位于美国的银行及金融服务企业，其前身为Meta金融集团旗下相关业务主体，2022年母公司将“Meta”商标出售给Meta Platforms后，正式启用现有名称。
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
CASH vs CPRX — 直观对比
营收规模更大
CASH
是对方的1.8倍
$152.6M
净利率更高
CPRX
高出8.1%
26.4%
两年增速更快
CPRX
近两年复合增速
21.0%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $276.3M | $152.6M |
| 净利润 | $72.9M | $52.7M |
| 毛利率 | — | 82.9% |
| 营业利润率 | — | 40.5% |
| 净利率 | 26.4% | 34.5% |
| 营收同比 | — | 7.6% |
| 净利润同比 | — | -5.8% |
| 每股收益（稀释后） | $3.35 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CASHCPRX
| Q1 26 | $276.3M | — | ||
| Q4 25 | $173.1M | $152.6M | ||
| Q3 25 | $186.7M | $148.4M | ||
| Q2 25 | $195.8M | $146.6M | ||
| Q1 25 | $274.8M | $141.4M | ||
| Q4 24 | $182.6M | $141.8M | ||
| Q3 24 | $179.5M | $128.7M | ||
| Q2 24 | $188.6M | $122.7M |
净利润CASHCPRX
| Q1 26 | $72.9M | — | ||
| Q4 25 | $35.2M | $52.7M | ||
| Q3 25 | $38.8M | $52.8M | ||
| Q2 25 | $42.1M | $52.1M | ||
| Q1 25 | $75.0M | $56.7M | ||
| Q4 24 | $30.0M | $55.9M | ||
| Q3 24 | $33.5M | $43.9M | ||
| Q2 24 | $44.9M | $40.8M |
毛利率CASHCPRX
| Q1 26 | — | — | ||
| Q4 25 | — | 82.9% | ||
| Q3 25 | — | 84.7% | ||
| Q2 25 | — | 85.9% | ||
| Q1 25 | — | 87.3% | ||
| Q4 24 | — | 84.7% | ||
| Q3 24 | — | 85.0% | ||
| Q2 24 | — | 87.4% |
营业利润率CASHCPRX
| Q1 26 | — | — | ||
| Q4 25 | 24.6% | 40.5% | ||
| Q3 25 | 25.9% | 44.7% | ||
| Q2 25 | 24.1% | 45.2% | ||
| Q1 25 | 33.2% | 44.8% | ||
| Q4 24 | 19.8% | 44.3% | ||
| Q3 24 | 20.9% | 39.6% | ||
| Q2 24 | 27.1% | 44.2% |
净利率CASHCPRX
| Q1 26 | 26.4% | — | ||
| Q4 25 | 20.3% | 34.5% | ||
| Q3 25 | 20.8% | 35.6% | ||
| Q2 25 | 21.5% | 35.6% | ||
| Q1 25 | 27.3% | 40.1% | ||
| Q4 24 | 16.4% | 39.4% | ||
| Q3 24 | 18.7% | 34.1% | ||
| Q2 24 | 23.8% | 33.2% |
每股收益（稀释后）CASHCPRX
| Q1 26 | $3.35 | — | ||
| Q4 25 | $1.57 | $0.40 | ||
| Q3 25 | $1.69 | $0.42 | ||
| Q2 25 | $1.81 | $0.41 | ||
| Q1 25 | $3.14 | $0.45 | ||
| Q4 24 | $1.23 | $0.44 | ||
| Q3 24 | $1.34 | $0.35 | ||
| Q2 24 | $1.78 | $0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $157.6M | $709.2M |
| 总债务越低越好 | $59.5M | — |
| 股东权益账面价值 | $850.7M | $954.3M |
| 总资产 | $7.1B | $1.1B |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资CASHCPRX
| Q1 26 | $157.6M | — | ||
| Q4 25 | $331.2M | $709.2M | ||
| Q3 25 | $120.6M | $689.9M | ||
| Q2 25 | $258.3M | $652.8M | ||
| Q1 25 | $254.2M | $580.7M | ||
| Q4 24 | $597.4M | $517.6M | ||
| Q3 24 | $158.3M | $442.3M | ||
| Q2 24 | $298.9M | $375.7M |
总债务CASHCPRX
| Q1 26 | $59.5M | — | ||
| Q4 25 | $33.5M | — | ||
| Q3 25 | $33.5M | — | ||
| Q2 25 | $33.4M | — | ||
| Q1 25 | $33.4M | — | ||
| Q4 24 | $33.4M | — | ||
| Q3 24 | $33.4M | — | ||
| Q2 24 | $33.3M | — |
股东权益CASHCPRX
| Q1 26 | $850.7M | — | ||
| Q4 25 | $854.5M | $954.3M | ||
| Q3 25 | $858.0M | $920.2M | ||
| Q2 25 | $819.0M | $856.0M | ||
| Q1 25 | $814.7M | $794.3M | ||
| Q4 24 | $758.3M | $727.6M | ||
| Q3 24 | $822.5M | $660.9M | ||
| Q2 24 | $748.4M | $608.7M |
总资产CASHCPRX
| Q1 26 | $7.1B | — | ||
| Q4 25 | $7.6B | $1.1B | ||
| Q3 25 | $7.2B | $1.1B | ||
| Q2 25 | $7.2B | $971.9M | ||
| Q1 25 | $7.0B | $908.9M | ||
| Q4 24 | $7.6B | $851.4M | ||
| Q3 24 | $7.5B | $772.0M | ||
| Q2 24 | $7.5B | $706.4M |
负债/权益比CASHCPRX
| Q1 26 | 0.07× | — | ||
| Q4 25 | 0.04× | — | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.04× | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $44.9M |
| 自由现金流经营现金流 - 资本支出 | — | $44.9M |
| 自由现金流率自由现金流/营收 | — | 29.4% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | 0.85× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CASHCPRX
| Q1 26 | — | — | ||
| Q4 25 | $108.3M | $44.9M | ||
| Q3 25 | $303.7M | $32.4M | ||
| Q2 25 | $30.4M | $71.3M | ||
| Q1 25 | $188.3M | $60.0M | ||
| Q4 24 | $-71.7M | $70.9M | ||
| Q3 24 | $143.1M | $72.9M | ||
| Q2 24 | $113.2M | $64.1M |
自由现金流CASHCPRX
| Q1 26 | — | — | ||
| Q4 25 | $104.1M | $44.9M | ||
| Q3 25 | $300.3M | — | ||
| Q2 25 | $27.7M | $71.3M | ||
| Q1 25 | $184.7M | — | ||
| Q4 24 | $-73.8M | $70.8M | ||
| Q3 24 | $138.8M | $72.6M | ||
| Q2 24 | $111.0M | $64.1M |
自由现金流率CASHCPRX
| Q1 26 | — | — | ||
| Q4 25 | 60.1% | 29.4% | ||
| Q3 25 | 160.9% | — | ||
| Q2 25 | 14.1% | 48.6% | ||
| Q1 25 | 67.2% | — | ||
| Q4 24 | -40.4% | 49.9% | ||
| Q3 24 | 77.3% | 56.4% | ||
| Q2 24 | 58.8% | 52.3% |
资本支出强度CASHCPRX
| Q1 26 | — | — | ||
| Q4 25 | 2.4% | 0.0% | ||
| Q3 25 | 1.8% | 0.0% | ||
| Q2 25 | 1.4% | 0.0% | ||
| Q1 25 | 1.3% | 0.0% | ||
| Q4 24 | 1.1% | 0.1% | ||
| Q3 24 | 2.4% | 0.2% | ||
| Q2 24 | 1.2% | 0.0% |
现金转化率CASHCPRX
| Q1 26 | — | — | ||
| Q4 25 | 3.08× | 0.85× | ||
| Q3 25 | 7.83× | 0.61× | ||
| Q2 25 | 0.72× | 1.37× | ||
| Q1 25 | 2.51× | 1.06× | ||
| Q4 24 | -2.39× | 1.27× | ||
| Q3 24 | 4.27× | 1.66× | ||
| Q2 24 | 2.52× | 1.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CASH
| Noninterest Income | $151.2M | 55% |
| Net Interest Income | $125.1M | 45% |
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
